|
|
|
|
|
|
|
|
|
|
In Research:
Introduction:
Patients with advanced-stage ovarian cancer generally undergo primary debulking surgery followed by platinum/taxane-based chemotherapy. Although postoperative introduction of taxane drug has improved the 5-year survival rate for advanced-stage ovarian cancer..... Clinicopathological characteristics, such as debulking status after primary surgery, are clinically considered important indicators of prognosis. However, recurrence after optimal debulking surgery occurs in some patients, while disease-free status after incomplete surgery is maintained in others......Therefore, these clinicopathological factors alone are insufficient for predicting prognosis and elucidating the pathological mechanisms of disease progression or recurrence. Molecular biology approaches can be used to identify new prognosis-related profiles leading to elucidation of pathological issues of advanced-stage serous ovarian cancer.
Meanwhile, there are no microarray kits for clinical diagnosis and management in patients with ovarian cancer yet."
Microarray technology has been developing very rapidly, and it has become relatively easy to analyze the expression levels of thousands of genes within cancer cells. Although many studies have reported the associations of gene expression profiles with prognoses in cancer patients [6]–[10], a limited number of such profiles are used in clinical settings. Microarray technology is clinically applied for predicting prognosis in breast cancer patients. MammaPrint ™ (Agendia BV, Amsterdam, the Netherlands) has been already put to practical use for the purpose.
Meanwhile, there are no microarray kits for clinical diagnosis and management in patients with ovarian cancer yet."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.